Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Great Point Partners LLC increased its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 15.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,701,510 shares of the company's stock after purchasing an additional 221,510 shares during the quarter. Outlook Therapeutics accounts for 2.4% of Great Point Partners LLC's investment portfolio, making the stock its 20th biggest holding. Great Point Partners LLC owned approximately 7.27% of Outlook Therapeutics worth $12,557,000 at the end of the most recent quarter.

Separately, LVW Advisors LLC acquired a new position in shares of Outlook Therapeutics during the 2nd quarter worth approximately $352,000. 11.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on OTLK shares. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Chardan Capital reiterated a "buy" rating and set a $53.00 price objective on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, Ascendiant Capital Markets reduced their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Outlook Therapeutics has a consensus rating of "Buy" and an average price target of $48.20.

Outlook Therapeutics Stock Performance

Shares of NASDAQ:OTLK remained flat at $5.58 during midday trading on Tuesday. The stock had a trading volume of 371,288 shares, compared to its average volume of 364,042. The firm has a market cap of $130.61 million, a price-to-earnings ratio of -0.49 and a beta of 0.64. The company's 50-day moving average is $7.33 and its 200 day moving average is $7.78. Outlook Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $18.00.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.23. Analysts expect that Outlook Therapeutics, Inc. will post -3.59 EPS for the current year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.